-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>
The "World's Most Admired Companies" list, produced by Fortune in partnership with Korn Ferry, surveyed more than 3,700 corporate executives, directors and analysts based on investment value, management and product quality, social responsibility, Nine criteria, including the ability to attract talent, rated 1,500 candidate companies in 52 industries
The All-Star 50 list is also voted by executives, directors and analysts of these companies
This year, the global new crown epidemic has entered its third year, economic development is struggling, and companies on the front line of the fight against the epidemic have regained attention
Since the outbreak of the new crown epidemic, Danaher has always paid attention to and actively participated in the fight against COVID-19, launched a variety of new detection technologies and products, helped the development of new crown vaccines and related therapies, supported the acceleration of the construction of the Great Wall of Immunization, and contributed to the building of global public health capacity
As a pioneer in the field of molecular diagnostics under the Danaher Group, Saipei continues to achieve technological breakthroughs and announced in September 2021 that its third-generation nucleic acid detection product Xpert Xpress CoV-2/Flu/RSV plus has been granted emergency use authorization by the US FDA (EUA), which adds a third gene target compared to the previous generation product to meet the challenges of future virus mutation
At the same time, Danaher provides a wide range of technologies and solutions in the field of biological products, helping scientific researchers and biopharmaceutical companies to accelerate the development of new crown vaccines and related therapies, and is committed to supporting the accelerated launch of new therapies and rapid expansion in a short period of time.
The Saint-Remy-sur- Avre plant in Delpharm is the first in France to produce a COVID-19 vaccine
Despite the uncertainty in the world throughout the pandemic, the Dan family continues to excel every day - launching breakthrough technologies and products in record time, in the DBS ethos of continuous improvement, and constantly surpassing ourselves for us Our customers provide strong support, provide help and service to the communities in which we live, and together contribute more to the realization of life's potential
